Novo Nordisk A/S (NVO)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE
Market Cap: $183.52B
Last updated: Nov 17, 2026 at 11:06 AM ET
Novo Nordisk A/S (NVO) Valuation Multiples
Novo Nordisk A/S (NVO) trades at 3.6x sales and 5.6x book value. Its P/S of 3.6x is below its 5-year median of 11.1x.
Current Multiples
NVO reports in DKK, so earnings multiples appear here only when its per-share earnings can be confirmed. Its free cash flow yield is 3.8%.
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | N/A |
| Price to sales | 3.6x |
| Price to book | 5.6x |
| EV/EBITDA | 6.9x |
| Price to FCF | 26.6x |
| EV/FCF | 28.6x |
| PEG | N/A |
| FCF yield | 3.8% |
Historical Medians
Against its 10-year medians, its P/S is 53.8% below 7.8x and its P/B is 72.9% below 20.7x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 3.6x | 11.1x | 7.8x |
| P/B | 5.6x | 27.1x | 20.7x |
Valuation History
Over the 10 year ends shown, its P/S ranged from 4.7x in 2025 to 13.8x in 2023. 2025 was the lowest of those years.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $50.88 | 4.7x | 7.4x |
| 2024 | $86.02 | 9.2x | 19.3x |
| 2023 | $103.45 | 13.8x | 29.3x |
| 2022 | $67.67 | 12.3x | 25.5x |
| 2021 | $56.00 | 11.7x | 23.7x |
| 2020 | $34.93 | 8.3x | 95.1x |
| 2019 | $28.94 | 7.5x | 105.4x |
| 2018 | $23.04 | 6.3x | 14.0x |
| 2017 | $26.84 | 7.7x | 16.5x |
| 2016 | $17.93 | 5.5x | 14.0x |
P/E history is shown only for companies that report in US dollars.
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About NVO
Is NVO stock overvalued?
GNG's valuation label for NVO is Undervalued.
What is NVO's price to sales ratio?
Novo Nordisk A/S has a price to sales ratio of 3.6x.
NVO pages: Overview, Dividends, Financials, Valuation, Competitors